Matinas BioPharma Holdings, Inc. (MTNB): R&D Expense
$85.0K
Year ended 2025-12-31
-82.8%
3-year compound annual growth
-64.2%
5-year compound annual growth
-33.8%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $85.0K | -99.3% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $11.43M | -21.1% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $14.49M | -13.1% | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | $16.68M | +14.4% | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | $14.58M | +1.6% | 2023-03-15, From 2021-01-01 |
| 2020-12-31 | $14.36M | +27.8% | 2022-03-11, From 2020-01-01 |
| 2019-12-31 | $11.23M | +65.5% | 2021-03-29, From 2019-01-01 |
| 2018-12-31 | $6.79M | -24.7% | 2020-03-09, From 2018-01-01 |
| 2017-12-31 | $9.01M | +128.3% | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | $3.95M | -25.4% | 2018-03-16, From 2016-01-01 |
| 2015-12-31 | $5.29M | +2.3% | 2018-03-16, From 2015-01-01 |
| 2014-12-31 | $5.18M | +193.8% | 2016-03-30, From 2014-01-01 |
| 2013-12-31 | $1.76M | n/a | 2015-03-31, From 2013-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Matinas BioPharma Holdings, Inc. (MTNB) | 2025-12-31 | $85.0K | -99.3% |
| Telomir Pharmaceuticals, Inc. (TELO) | 2025-12-31 | $2.44M | +9.0% |
| Ensysce Biosciences, Inc. (ENSC) | 2025-12-31 | $10.38M | +43.7% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $122.0K | +3.4% |
| Serina Therapeutics, Inc. (SER) | 2025-12-31 | $13.15M | +75.9% |
| Oncolytics Biotech Inc (ONCY) | 2025-12-31 | $13.31M | -13.8% |
| OS Therapies Inc (OSTX) | 2025-12-31 | $16.36M | +476.3% |
| Rocket One Inc. (RKTO) | 2025-12-31 | $5.95M | +83.0% |
| Silo Pharma, Inc. (SILO) | 2025-12-31 | $2.16M | -8.8% |
Compare MTNB, TELO, ENSC, CVSI side by side · Screen every company in Pharmaceutical Preparations ↗